OKYO Pharma Rings Nasdaq Opening Bell
Ticker: OKYO · Form: 6-K · Filed: Dec 19, 2025 · CIK: 1849296
Sentiment: neutral
Topics: ceremony, visibility, press-release
Related Tickers: OKYO
TL;DR
OKYO Pharma execs ringing Nasdaq bell today - big visibility play!
AI Summary
On December 19, 2025, OKYO Pharma Ltd announced that Executive Chairman and Founder, Gabriele Cerrone, along with the management team, will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York. The ceremony is scheduled to take place today, starting at 9:15 AM.
Why It Matters
This event signifies a milestone for OKYO Pharma, potentially increasing visibility and investor interest as they participate in a prominent stock exchange ceremony.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a ceremonial event with no direct financial or operational impact disclosed.
Key Players & Entities
- OKYO Pharma Ltd (company) — Registrant
- Gabriele Cerrone (person) — Executive Chairman and Founder
- Nasdaq MarketSite (company) — Location of event
- December 19, 2025 (date) — Date of announcement and event
FAQ
What is the purpose of OKYO Pharma Ltd ringing the Nasdaq Opening Bell?
The filing states that the Executive Chairman and Founder, Gabriele Cerrone, and the OKYO management team will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York on December 19, 2025.
Who is representing OKYO Pharma Ltd at the Nasdaq Opening Bell ceremony?
Gabriele Cerrone, the Executive Chairman and Founder, along with the OKYO management team, will be present.
When is the Nasdaq Opening Bell ceremony scheduled to take place?
The ceremony is scheduled for December 19, 2025, starting at 9:15 AM.
Where is the Nasdaq Opening Bell ceremony being held?
The ceremony will be held at the Nasdaq MarketSite in Times Square, New York.
What type of company is OKYO Pharma Ltd?
OKYO Pharma Ltd is classified under the Standard Industrial Classification code 2836, which pertains to Biological Products (No Diagnostic Substances).
Filing Stats: 403 words · 2 min read · ~1 pages · Grade level 15.6 · Accepted 2025-12-19 07:00:19
Filing Documents
- form6-k.htm (6-K) — 22KB
- ex99-1.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-25-028440.txt ( ) — 39KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: December 19, 2025 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 News Announcement, dated December 19, 2025 4